Skip to content

Randomized double-blind parallel controlled clinical trail of Chenpi enzyme in the treatment of hyperlipidemia

Randomized double-blind parallel controlled clinical trail of Chenpi enzyme in the treatment of hyperlipidemia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003313
Enrollment
Unknown
Registered
2020-05-19
Start date
2020-05-18
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

Sponsors

Guangdong Province Traditional Chinese Medical Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years; 2. Patients with dyslipidemia; 3. The cardiovascular risk was assessed as low risk patients; 4. Those who voluntarily participate in the research and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who were taking antilipidemic drugs within 3 months before inclusion; 2. Patients with nephrotic syndrome, hypothyroidism, renal failure, liver disease and systemic lupus erythematosus; 3. Patients with myeloma, glycogen accumulation, fatty atrophy, acute porphyria and polycystic ovary syndrome; 4. Patients taking drugs related to lipid metabolism, such as diuretics, beta blockers, glucocorticoids, metformin, insulin and contraceptives; 5. Patients whose systolic blood pressure is still >= 180mmhg or diastolic blood pressure is still >= 110mhg after treatment; 6. After oral drug treatment, the blood glucose is still >= 11.1mmol/L Of patients; 7. TG >= 5.65mmol/L Those who; 8. Patients with heart, liver, kidney, hematopoietic system, immune system and other systemic serious diseases; 9. Pregnant or lactating women or those who plan to be pregnant during the trial period or their spouses plan to be pregnant; 10. Patients with allergic constitution, possible allergy to the drug or psychosis; 11. Other patients who cannot cooperate for a long time.

Design outcomes

Primary

MeasureTime frame
TC;HDL-C;LDL-C;TG;

Secondary

MeasureTime frame
UA;GLU;BMI;The proportion of blood lipid components meet the standard;CRP;

Countries

China

Contacts

Public ContactXinyan Chen

Guangdong Province Traditional Chinese Medical Hospital

chenxinyancxy@163.com+86 13539984767

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026